Drug
Datopotamab deruxtecan clinical trials
Also written Dato-DXd, DS-1062a and DATROWAY®.
- studies test it
- 35
- open now
- 20
- in phase 3
- 17
- first study started
- 2010
Keep track of what changes. Save the datopotamab deruxtecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
35 studies that test it; most in 2024 (7)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 6 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 17
- Phase 3
- 17
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 10
AstraZeneca (18) · Daiichi Sankyo (7) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Fudan University (1) · Ana C Garrido-Castro, MD (1) · Latin American Cooperative Oncology Group (1) · Nancy Lin, MD (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Durvalumab (6) · Rilvegostomig (4) · Pembrolizumab (4) · Carboplatin (3) · Osimertinib (2) · Pemetrexed (2) · Cisplatin (2) · Ado-Trastuzumab Emtansine (2)
Studies
Open first, then newest update. How each study uses datopotamab deruxtecan is read from its arms, and is right about nine times in ten.
Testing it · 35
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingPhase 1/2Daiichi SankyoNCT07890714Written as Dato-DXd
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Dato-DXd
- A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2AstraZenecaNCT07098338Written as Dato-DXd
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsRecruitingPhase 3AstraZenecaNCT07291037Written as Datopotamab deruxtecan (Dato-DXd)
- A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast CancerRecruitingPhase 3AstraZenecaNCT07205822Written as Dato-DXd
- An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.RecruitingPhase 4AstraZenecaNCT07357597Written as Datopotamab Deruxtecan (Dato-DXd)
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingPhase 3AstraZenecaNCT06103864Written as Dato-DXd
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsRecruitingPhase 3AstraZenecaNCT06357533Written as Datopotamab Deruxtecan
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Datopotamab deruxtecan (Dato-DXd)
- A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid TumorsRecruitingPhase 1/2AstraZenecaNCT06130553Written as Datopotamab deruxtecan
- TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdRecruitingPhase 2Ana C Garrido-Castro, MDNCT06533826Written as Datopotamab Deruxtecan
- Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingPhase 3AstraZenecaNCT06350097Written as Datopotamab Deruxtecan
- A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)RecruitingPhase 2Latin American Cooperative Oncology GroupNCT06822543Written as Datopotamab deruxtecan
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaRecruitingPhase 2/3Daiichi SankyoNCT07129993Written as Dato-DXd
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEsRecruitingPhase 2Nancy Lin, MDNCT06176261Written as Datopotamab Deruxtecan
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingPhase 3AstraZenecaNCT07720284Written as Dato-DXd
- A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07535437Written as Dato-DXd
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Datopotamab deruxtecan
- PREDICT-RD: ctDNA Surveillance in TNBC With Residual DiseaseRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07069595Written as Datopotamab deruxtecan
- Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain MetastasesRecruitingPhase 2Medical University of ViennaNCT05866432Written as Datopotamab deruxtecan
See all 35 studies that test datopotamab deruxtecan →
Given in every arm · 12 — datopotamab deruxtecan is usual care beside what is tested
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingPhase 1/2AstraZenecaNCT05417594Written as Datopotamab Deruxtecan (Dato-DXd)
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingPhase 2AstraZenecaNCT05489211Written as Datopotamab deruxtecan (Dato-DXd)
- GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)Not yet recruitingPhase 1/2Eddingpharm (Zhuhai) Co., Ltd.NCT07738341Written as Datopotamab Deruxtecan (Dato-DXd)
- Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerRecruitingPhase 2Queen Mary University of LondonNCT06954480Written as Datopotamab Deruxtecan (Dato-DXd)
- A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT06508216Written as Dato-DXd
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingPhase 1/2AstraZenecaNCT04644068Written as Dato-DXd
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsActive, not recruitingPhase 1Daiichi SankyoNCT06244485Written as Dato-DXd
- First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Active, not recruitingPhase 1Daiichi Sankyo Co., Ltd.NCT03401385Written as Datopotamab Deruxtecan (Dato-DXd)
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT03742102Written as Datopotamab deruxtecan
- Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 1AstraZenecaNCT04612751Written as Datopotamab deruxtecan
- A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsActive, not recruitingPhase 1Cullinan Therapeutics Inc.NCT05117476Written as Datopotamab deruxtecan-dlnk (Dato-DXd)
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingPhase 2AstraZenecaNCT03944772Written as Datopotamab deruxtecan
Codes
What other systems call datopotamab deruxtecan · ClinicalTrials.gg INT002176
- MeSH (NLM) C000731951datopotamab deruxtecanOne source NLM
- UNII (FDA) GD2OWY1DTKDATOPOTAMAB DERUXTECANConfirmed FDA, NLM
- NCI Thesaurus C151967Datopotamab DeruxtecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731951 | datopotamab deruxtecan | One source NLM |
| UNII (FDA) | GD2OWY1DTK | DATOPOTAMAB DERUXTECAN | Confirmed FDA, NLM |
| NCI Thesaurus | C151967 | Datopotamab Deruxtecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.